Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AIM ImmunoTech Inc AIM

Healthcare Biotechnology
AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called... see more

Recent & Breaking News (NYSEAM:AIM)

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

GlobeNewswire 19 hours ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

GlobeNewswire 7 days ago

AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs

GlobeNewswire 10 days ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

GlobeNewswire April 11, 2024

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

GlobeNewswire April 10, 2024

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire April 2, 2024

AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference

GlobeNewswire March 28, 2024

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast

GlobeNewswire March 26, 2024

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

GlobeNewswire March 25, 2024

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

GlobeNewswire March 22, 2024

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

GlobeNewswire March 20, 2024

AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity

GlobeNewswire March 15, 2024

AIM ImmunoTech Announces Launch of CEO Corner Platform

GlobeNewswire March 7, 2024

AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update

GlobeNewswire February 29, 2024

AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer

GlobeNewswire February 14, 2024

AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

GlobeNewswire February 8, 2024

AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer

GlobeNewswire January 24, 2024

AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca's Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer

GlobeNewswire January 22, 2024

AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

GlobeNewswire January 10, 2024

AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting

Business Wire January 5, 2024